Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice.
Bortezomib, a novel proteasome inhibitor approved for the treatment of cancer in adults, has recently been introduced in pediatric clinical trials. Any tissue-specific side effects on bone development have to our knowledge not yet been explored. To address this, we experimentally studied the effects...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3511518?pdf=render |
| _version_ | 1818127453052207104 |
|---|---|
| author | Emma Eriksson Farasat Zaman Dionisios Chrysis Henrik Wehtje Terhi J Heino Lars Sävendahl |
| author_facet | Emma Eriksson Farasat Zaman Dionisios Chrysis Henrik Wehtje Terhi J Heino Lars Sävendahl |
| author_sort | Emma Eriksson |
| collection | DOAJ |
| description | Bortezomib, a novel proteasome inhibitor approved for the treatment of cancer in adults, has recently been introduced in pediatric clinical trials. Any tissue-specific side effects on bone development have to our knowledge not yet been explored. To address this, we experimentally studied the effects of bortezomib in vivo in young mice and in vitro in organ cultures of rat metatarsal bones and human growth plate cartilage, as well as in a rat chondrocytic cell line. We found that bortezomib while efficiently blocking the ubiquitin/proteasome system (UPS) caused significant growth impairment in mice, by increasing resting/stem-like chondrocyte apoptosis. Our data support a local action of bortezomib, directly targeting growth plate chondrocytes leading to decreased bone growth since no suppression of serum levels of insulin-like growth factor-I (IGF-I) was observed. A local effect of bortezomib was confirmed in cultured rat metatarsal bones where bortezomib efficiently caused growth retardation in a dose dependent and irreversible manner, an effect linked to increased chondrocyte apoptosis, mainly of resting/stem-like chondrocytes. The cytotoxicity of bortezomib was also evaluated in a unique model of cultured human growth plate cartilage, which was found to be highly sensitive to bortezomib. Mechanistic studies of apoptotic pathways indicated that bortezomib induced activation of p53 and Bax, as well as cleavage of caspases and poly-ADP-ribose polymerase (PARP) in exposed chondrocytes. Our observations, confirmed in vivo and in vitro, suggest that bone growth could potentially be suppressed in children treated with bortezomib. We therefore propose that longitudinal bone growth should be closely monitored in ongoing clinical pediatric trials of this promising anti-cancer drug. |
| first_indexed | 2024-12-11T07:17:35Z |
| format | Article |
| id | doaj.art-f903b25246c94137ab0338c6b94469a0 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T07:17:35Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f903b25246c94137ab0338c6b94469a02022-12-22T01:16:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01711e5052310.1371/journal.pone.0050523Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice.Emma ErikssonFarasat ZamanDionisios ChrysisHenrik WehtjeTerhi J HeinoLars SävendahlBortezomib, a novel proteasome inhibitor approved for the treatment of cancer in adults, has recently been introduced in pediatric clinical trials. Any tissue-specific side effects on bone development have to our knowledge not yet been explored. To address this, we experimentally studied the effects of bortezomib in vivo in young mice and in vitro in organ cultures of rat metatarsal bones and human growth plate cartilage, as well as in a rat chondrocytic cell line. We found that bortezomib while efficiently blocking the ubiquitin/proteasome system (UPS) caused significant growth impairment in mice, by increasing resting/stem-like chondrocyte apoptosis. Our data support a local action of bortezomib, directly targeting growth plate chondrocytes leading to decreased bone growth since no suppression of serum levels of insulin-like growth factor-I (IGF-I) was observed. A local effect of bortezomib was confirmed in cultured rat metatarsal bones where bortezomib efficiently caused growth retardation in a dose dependent and irreversible manner, an effect linked to increased chondrocyte apoptosis, mainly of resting/stem-like chondrocytes. The cytotoxicity of bortezomib was also evaluated in a unique model of cultured human growth plate cartilage, which was found to be highly sensitive to bortezomib. Mechanistic studies of apoptotic pathways indicated that bortezomib induced activation of p53 and Bax, as well as cleavage of caspases and poly-ADP-ribose polymerase (PARP) in exposed chondrocytes. Our observations, confirmed in vivo and in vitro, suggest that bone growth could potentially be suppressed in children treated with bortezomib. We therefore propose that longitudinal bone growth should be closely monitored in ongoing clinical pediatric trials of this promising anti-cancer drug.http://europepmc.org/articles/PMC3511518?pdf=render |
| spellingShingle | Emma Eriksson Farasat Zaman Dionisios Chrysis Henrik Wehtje Terhi J Heino Lars Sävendahl Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. PLoS ONE |
| title | Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. |
| title_full | Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. |
| title_fullStr | Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. |
| title_full_unstemmed | Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. |
| title_short | Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. |
| title_sort | bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice |
| url | http://europepmc.org/articles/PMC3511518?pdf=render |
| work_keys_str_mv | AT emmaeriksson bortezomibiscytotoxictothehumangrowthplateandpermanentlyimpairsbonegrowthinyoungmice AT farasatzaman bortezomibiscytotoxictothehumangrowthplateandpermanentlyimpairsbonegrowthinyoungmice AT dionisioschrysis bortezomibiscytotoxictothehumangrowthplateandpermanentlyimpairsbonegrowthinyoungmice AT henrikwehtje bortezomibiscytotoxictothehumangrowthplateandpermanentlyimpairsbonegrowthinyoungmice AT terhijheino bortezomibiscytotoxictothehumangrowthplateandpermanentlyimpairsbonegrowthinyoungmice AT larssavendahl bortezomibiscytotoxictothehumangrowthplateandpermanentlyimpairsbonegrowthinyoungmice |